ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Machine learning-driven conditional survival prediction model for atypical teratoid/rhabdoid tumor.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAtypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly malignant pediatric brain tumor with dismal prognosis. We aimed to characterize dynamic survival patterns using conditional survival (CS) and annual hazard rate (AHR) analyses, identify key prognostic factors through machine learning (ML)-based feature selection, and develop an interpretable CS-nomogram for individualized prognostication.
methodsData of AT/RT patients diagnosed between 2000 and 2022 were obtained from the SEER database. CS and AHR analyses were performed to assess temporal survival dynamics. Four complementary algorithms-LASSO regression, Boruta algorithm, stepwise regression, and best subset regression-were used for feature selection. The final CS-nomogram was validated using ROC curves, calibration plots, and decision curve analysis (DCA). Model interpretability was evaluated with Shapley additive explanations (SHAP), and a web-based calculator was created for clinical application.
resultsA total of 382 patients were analyzed. The 5-year survival probability at diagnosis was 34.11%,but increased to 95.14% among those surviving beyond 4 years, while AHR declined from 44.76% in the first year to < 5% after 5 years. Tumor extension, radiotherapy, and chemotherapy were consistently identified as key predictors. The CS-nomogram showed excellent discrimination (1-, 3-, and 5-year AUCs: 0.860, 0.796, and 0.762 in training; 0.857, 0.764, and 0.744 in validation), and SHAP analysis confirmed radiotherapy, chemotherapy, and tumor extension as major contributors.
conclusionCS analysis revealed a marked improvement in long-term survival among AT/RT survivors. The ML-based CS-nomogram provides a robust, interpretable, and clinically applicable tool for dynamic, individualized prognostication and personalized follow-up planning in this rare malignancy.
Indexed as
Identifiers
42262569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.